Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Change in Receivables (2023 - 2025)

Historic Change in Receivables for BioXcel Therapeutics (BTAI) over the last 3 years, with Q3 2025 value amounting to -$17000.0.

  • BioXcel Therapeutics' Change in Receivables rose 9789.86% to -$17000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3000.0, marking a year-over-year increase of 9959.02%. This contributed to the annual value of $60000.0 for FY2024, which is 13389.83% up from last year.
  • Latest data reveals that BioXcel Therapeutics reported Change in Receivables of -$17000.0 as of Q3 2025, which was up 9789.86% from $17000.0 recorded in Q2 2025.
  • In the past 5 years, BioXcel Therapeutics' Change in Receivables registered a high of $434000.0 during Q2 2024, and its lowest value of -$809000.0 during Q3 2024.
  • Over the past 3 years, BioXcel Therapeutics' median Change in Receivables value was $35000.0 (recorded in 2023), while the average stood at -$22545.5.
  • Within the past 5 years, the most significant YoY rise in BioXcel Therapeutics' Change in Receivables was 77714.29% (2024), while the steepest drop was 36611.84% (2024).
  • Over the past 3 years, BioXcel Therapeutics' Change in Receivables (Quarter) stood at -$664000.0 in 2023, then soared by 119.28% to $128000.0 in 2024, then plummeted by 113.28% to -$17000.0 in 2025.
  • Its Change in Receivables was -$17000.0 in Q3 2025, compared to $17000.0 in Q2 2025 and -$131000.0 in Q1 2025.